76
|
Basso D, Panozzo MP, Fabris C, Meggiato T, Faggian D, Fogar P, Scalon P, Del Favero G, Plebani M, Burlina A, Naccarato R. Does serum CAR-3 play a role in pancreatic cancer diagnosis? Oncology 1991; 48:22-5. [PMID: 1987495 DOI: 10.1159/000226888] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A new tumour marker, CAR-3, was isolated using the monoclonal antibody technique and measured in the sera of 27 patients with pancreatic cancer, 25 chronic pancreatitis, 30 extra-pancreatic diseases and in that of 18 healthy controls in order (1) to evaluate the diagnostic role of CAR-3 in patients with pancreatic cancer and (2) to ascertain whether liver dysfunction influences CAR-3 serum levels. The increased levels were found in 12/27 patients with pancreatic cancer (sensitivity 44.4%). No increase was found in patients with chronic pancreatitis, whereas abnormal levels were found in patients with other gastrointestinal diseases, especially those of the liver and biliary tract. Correlations were found between serum CAR-3 and (1) total bilirubin and (2) alkaline phosphatase. In conclusion, CAR-3, an antigen structurally related to CA 19-9, does not appear to be accurate enough to be considered a tumour marker. Cholestasis seems to increase CAR-3 levels as well as those of other glycoproteic tumour markers, probably by interfering with the hepatic clearance of these substances.
Collapse
|
77
|
Plebani M, Faggian D, Masiero M, Giacomini A, Burlina A. CA 19-9 and CA 125 determination by immunoluminometric assay. JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY. ZEITSCHRIFT FUR KLINISCHE CHEMIE UND KLINISCHE BIOCHEMIE 1990; 28:919-21. [PMID: 2081962 DOI: 10.1515/cclm.1990.28.12.919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We evaluated a new immunoluminometric technique (ILMA) for the measurement of the cancer antigens, CA 19-9 and CA 125 in serum. A satisfactory reproducibility was found, coefficients of variation ranging from 4.2 to 7.3% in within-run and between-run assays. The linearity of tests was maintained over a wide concentration range. Mean analytical recovery was 94% for CA 19-9 and 98% for CA 125. A significant agreement between results obtained by immunoradiometric assays and evaluated methods was found both for CA 125 (ILMA = 0.917 IRMA + 1.048; r = 0.966; n = 98) and CA 19-9 (ILMA = 1.156 IRMA + 0.996; r = 0.995; n = 100).
Collapse
|
78
|
Pradella M, Mantovani G, Sirianni F, Burlina A. Three-minute whole-blood cholesterol screening test evaluated. Clin Chem 1990; 36:1994-5. [PMID: 2242590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
79
|
Pradella M, Mantovani G, Sirianni F, Burlina A. Three-minute whole-blood cholesterol screening test evaluated. Clin Chem 1990. [DOI: 10.1093/clinchem/36.11.1994] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
80
|
Plebani M, Giacomini A, Floreani A, Chiaramonte M, Soffiati G, Naccarato R, Burlina A. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. LA RICERCA IN CLINICA E IN LABORATORIO 1990; 20:269-74. [PMID: 2075379 DOI: 10.1007/bf02900712] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We studied the behavior of some biochemical markers of fibrosis, the aminoterminal propeptide of type III procollagen (P-III-P), laminin, hyaluronate and fibronectin, in the sera of patients with primary biliary cirrhosis (PBC). Significant increases were found in serum laminin, hyaluronate and P-III-P and, more important, a significant correlation was found between the histological stage of the disease and serum hyaluronate. This parameter seems to distinguish between early PBC (I and II stages) and advanced disease with fibrosis. Moreover, a correlation between the histological stage and serum levels of both laminin and P-III-P was observed. Serum laminin, however, increases particularly in advanced disease, whereas high levels of sP-III-P are already present in the early stage. Finally, no significant differences were found between the plasma fibronectin levels of patients with primary biliary cirrhosis and those of controls.
Collapse
|
81
|
Diodati G, Bonetti P, Plebani M, Giacomini A, Rugge M, Realdi G, Burlina A. Cryptogenic chronic active liver disease. Evaluation of serum aminoterminal peptide of type III procollagen as a marker of histological activity. LA RICERCA IN CLINICA E IN LABORATORIO 1990; 20:253-9. [PMID: 2075377 DOI: 10.1007/bf02900710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Sera from 64 patients with HBsAg-negative chronic liver disease with or without cirrhosis were investigated for aminoterminal peptide of type III procollagen (sP-III-P) as a suitable marker of hepatic fibrosis; 244 healthy control subjects were included in the study. A close correlation (p less than 0.01) between sP-III-P levels and histological activity was observed; on the contrary, no correlation was found between the same serum marker of liver fibroplasia and biochemical activity or clinical severity of the disease. We conclude that sP-III-P as a suitable marker of liver overload of collagen fibers is strongly correlated with the histological activity of the disease. Local immune reactions produce soluble substances that might stimulate fibroblastic activity. The test has a significant sensitivity and a very high specificity as a marker of chronic liver disease with histological activity.
Collapse
|
82
|
|
83
|
Plebani M, Masiero M, Burlina AP, Chiozza ML, Scanarini M, Burlina A. Measurement of melatonin in blood by radioimmunoassay. Analytical considerations and clinical usefulness. Childs Nerv Syst 1990; 6:220-1. [PMID: 2383877 DOI: 10.1007/bf01850977] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Melatonin assay has proved to be clinically useful for the diagnosis and investigation of several diseases (e.g., Cushing's syndrome, depressive disorders). We have evaluated the analytical performance of a radioimmunoassay for the determination of melatonin in plasma. The interference of some anticoagulants has been investigated, as well as the preliminary extraction of the hormone using a liquid-liquid and a solid-phase extraction method. The variation coefficients of the assay, within and between runs, were between 3.8% and 9.2% and between 4.1% and 10.5%, respectively. The well-documented circadian rhythm of melatonin secretion was confirmed in our healthy subjects. Preliminary results appear to confirm the significance of melatonin measurement in neurosurgical patients.
Collapse
|
84
|
Di Mario F, Angonese C, Del Favero G, Aggio L, Meggiato T, Scalon P, Basso D, Plebani M, Burlina A, Naccarato R. [Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis]. GIORNALE DI CLINICA MEDICA 1990; 71:435-41. [PMID: 2258026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Several studies are present in the literature about the efficacy of medical treatment with biliary acid, orally administered, on the symptomatic gallstone patients. Both this drugs act, with different mechanisms, on the same pathophysiological pathway, represented by the supersaturated bile in cholesterol. Aim of the present investigation was to study the possible modifications of serum bile acids pattern and of lipoproteins in a large sample of gallstone patients under long-term treatment with biliary acids. One hundred and twelve patients with radiolucent gallstones entered the study; 54 received chenodeoxycholic acid (CDCA) and 58 ursodeoxycholic (UDCA) at dosage of 15 mg/kg/daily. Blood samples for determination of serum cholesterol, triglycerides, phospholipids, lipoproteins, total and fractionated biliary acids were collected from each subjects every three months for a mean "follow-up" of 24 months. The levels of serum cholesterol, triglycerides and phospholipids showed a mild decrease only in the patients under therapy with CDCA, while no modifications were detected using UDCA. The same was found for two other parameters, HDL-cholesterol and lipoproteins, with both treatments during the overall period of follow-up. The biliary acids levels showed a significant increase only in the patients treated with CDCA, but no differences were found between "responders" and "non responders" to the therapy.
Collapse
|
85
|
Plebani M, Paleari CD, Masiero M, Faggian D, Burlina A. Fluorescence polarization immunoassay for cyclosporine A determination in whole blood. Ther Drug Monit 1990; 12:284-7. [PMID: 2349614 DOI: 10.1097/00007691-199005000-00013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A fluorescence polarization immunoassay (FPIA) for cyclosporine A (CsA) determination in blood was evaluated. The method demonstrated a good reproducibility both in within-run and between-run assays. The linearity range was 35-990 micrograms/L. Comparison of measurements in patients' whole blood with radioimmunoassay results showed higher estimates by the FPIA despite the good correlation coefficient. Finally, a poor agreement was observed between the evaluated method and the high-performance liquid chromatographic technique for CsA determination.
Collapse
|
86
|
Basso D, Panozzo MP, Fabris C, del Favero G, Meggiato T, Fogar P, Meani A, Faggian D, Plebani M, Burlina A. Oxygen derived free radicals in patients with chronic pancreatic and other digestive diseases. J Clin Pathol 1990; 43:403-5. [PMID: 1695229 PMCID: PMC502446 DOI: 10.1136/jcp.43.5.403] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
To ascertain modifications in the activation products derived from oxygen free radicals in patients with chronic pancreatic and extra-pancreatic diseases, lipid peroxide activity was measured in the sera of 40 control subjects, 28 patients with pancreatic cancer, 49 with chronic pancreatitis, and 53 with extra-pancreatic diseases. In 142 of the subjects, elastase 1, amylase, and pancreatic isoamylase activities were also determined. Increased lipid peroxide activities were found in some patients with both chronic pancreatic and extra-pancreatic diseases. Patients with chronic pancreatitis studied during relapse had higher activities of lipid peroxides than those without active disease. No difference was found between the values in patients with pancreatic cancer with liver metastases and those without. Correlations were found between lipid peroxides and both amylase and pancreatic isoamylase activities; no correlation was detected between lipid peroxides and elastase 1. In benign biliary tract disease a correlation was detected between lipid peroxides and alanine aminotransferase and alkaline phosphatase activities. In all patients, however, a correlation was found between alkaline phosphatase and lipid peroxide activities. It is concluded that activation of oxygen derived free radicals occurs in chronic pancreatic as well as in extra-pancreatic disease; it seems to reflect the degree of inflammation.
Collapse
|
87
|
Pradella M, Burlina A. Satisfaction of medically useful criteria. Arch Pathol Lab Med 1990; 114:449-50. [PMID: 2369462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
88
|
Plebani M, Di Mario F, Dal Santo PL, Faggian D, Germana B, Vianello F, Naccarato R, Burlina A. Measurement of pepsinogen group I in endoscopic gastroduodenal biopsies. Clin Chem 1990. [DOI: 10.1093/clinchem/36.4.682] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
A technique for determining pepsinogen group I (PGI) concentrations in endoscopic gastroduodenal biopsies is described and validated. This method has a good precision (intra-assay CVs 4.1% to 8.4%; between-assay CVs 4.6% to 9.3%), and analytical recovery is satisfactory (94% to 102%). Results were uninfluenced by the storage interval of the samples. At PGI-producing sites (i.e., fundus, corpus) peptic activity was greater than in the antrum and duodenum. PGI concentrations in serum and in gastroduodenal biopsies were not correlated. This simple, reliable method can quantify better than other assays peptic activity in humans, without being influenced by gastric secretory volumes. It will also facilitate prospective studies on the effect of various secretagogues in vivo and evaluations of the influence of anti-ulcer drugs on peptic secretion.
Collapse
|
89
|
Plebani M, Di Mario F, Dal Santo PL, Faggian D, Germana B, Vianello F, Naccarato R, Burlina A. Measurement of pepsinogen group I in endoscopic gastroduodenal biopsies. Clin Chem 1990; 36:682-4. [PMID: 2323049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A technique for determining pepsinogen group I (PGI) concentrations in endoscopic gastroduodenal biopsies is described and validated. This method has a good precision (intra-assay CVs 4.1% to 8.4%; between-assay CVs 4.6% to 9.3%), and analytical recovery is satisfactory (94% to 102%). Results were uninfluenced by the storage interval of the samples. At PGI-producing sites (i.e., fundus, corpus) peptic activity was greater than in the antrum and duodenum. PGI concentrations in serum and in gastroduodenal biopsies were not correlated. This simple, reliable method can quantify better than other assays peptic activity in humans, without being influenced by gastric secretory volumes. It will also facilitate prospective studies on the effect of various secretagogues in vivo and evaluations of the influence of anti-ulcer drugs on peptic secretion.
Collapse
|
90
|
Basso D, Fabris C, Del Favero G, Piccoli A, Angonese C, Pasquali C, Castoro C, Plebani M, Leandro G, Burlina A. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer? THE ITALIAN JOURNAL OF GASTROENTEROLOGY 1990; 22:1-6. [PMID: 2131920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Serum CA 19-9 was determined in 83 control subjects, 99 patients with pancreatic cancer, 104 with chronic pancreatitis and 137 with extra-pancreatic diseases mainly of gastrointestinal origin in order to evaluate whether hepatic factors can influence circulating CA 19-9 in pancreatic cancer. Sensitivity, specificity and accuracy of this test in determining pancreatic malignancy were: 74%, 83% and 57%. We divided patients into two groups: group A (159 cases) and group B (181 cases) with and without anatomical liver damage (presence of primary or metastatic cancer, cirrhosis, hepatitis, steatofibrosis, cholangitis). Group A presented higher CA 19-9 values as compared to group B. Significant correlations were found in group B but not in group A between CA 19-9 and ALT, ALP and total bilirubin. Multiple regression analysis (CA 19-9 dependent and ALT, ALP and total bilirubin predictor variables) was significant only in group B. The standardized partial regression coefficients found to be significant were those of ALP and total bilirubin. We can conclude that CA 19-9 is an index of pancreatic cancer with satisfactory sensitivity and specificity. The presence of anatomical liver damage seems to increase the value of this index, probably releasing CA 19-9 into the bloodstream. Extra-hepatic cholestasis may also be an important factor in elevating CA 19-9 probably by reducing the hepatic catabolism of this glycoprotein.
Collapse
|
91
|
Plebani M, Basso D, Fabris C, Meggiato T, Del Favero G, Panozzo MP, Fogar P, Faggian D, Angonese C, Burlina A. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases. KLINISCHE WOCHENSCHRIFT 1989; 67:1029-32. [PMID: 2586008 DOI: 10.1007/bf01727004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Serum TATI (tumor-associated trypsin inhibitor) was measured in 41 control subjects, 30 patients with pancreatic cancer, 53 with chronic pancreatitis, and 47 with extrapancreatic diseases, mainly of gastrointestinal origin. TATI was found to be elevated in some subjects in all groups of patients; patients with chronic pancreatitis studied during an acute exacerbation of the disease had the highest percentage (68%) of pathological values. TATI was found to be correlated with elastase 1, tissue polypeptide antigen, and total and pancreatic isoamylase. A significant relationship was also found between TATI and serum creatinine levels.
Collapse
|
92
|
Plebani M, Masiero M, Paleari CD, Faggian D, Burlina A. Evaluation of the Incstar Cyclo-Trac sp kit for the determination of cyclosporine in blood. Clin Biochem 1989; 22:345-7. [PMID: 2805337 DOI: 10.1016/s0009-9120(89)80030-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We measured cyclosporine in whole blood samples from renal and heart transplant patients by high performance liquid chromatography and by two radioimmunoassays with use of specified monoclonal antibodies. In particular, we evaluated the analytical performance of a new specific radioimmunoassay with an iodinated tracer. The reproducibility of the method is satisfactory (within-run CV 7.1 to 9.5% and between-run CV 7.2 to 10.3%). The limit of detection is 10.3 micrograms/L and the analytical recovery between 99 and 114%. The results obtained with samples from both renal heart transplant patients agree well with those obtained by HPLC and by a specific RIA that uses a tritiated tracer.
Collapse
|
93
|
Farinati F, Plebani M, Faggian D, Di Mario F, Fanton MC, Valiante F, Burlina A, Naccarato R. TAG-72 serum determination in early and advanced gastric cancer. Int J Cancer 1989; 44:378-9. [PMID: 2759743 DOI: 10.1002/ijc.2910440232] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
94
|
Plebani M, Masiero M, Paleari CD, Sciacovelli L, Faggian D, Burlina A. High-performance liquid chromatography for cyclosporin measurement: comparison with radioimmunoassay. J Chromatogr A 1989; 476:93-8. [PMID: 2777999 DOI: 10.1016/s0021-9673(01)93859-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The large inter-patient variability in cyclosporin pharmacokinetics coupled with the agent's narrow therapeutic index with adverse effects resulting from supratherapeutic levels, necessitates individualization of drug dosage and therapeutic monitoring of cyclosporin blood levels. The performance of a liquid chromatographic method for the measurement of cyclosporin was evaluated and the results obtained by this method and by a specific radioimmunoassay were correlated. The method described is sensitive, selective, reproducible and easier to perform than other chromatographic methods. It is suitable for the daily measurement of cyclosporin in batches of up to 40 samples and the results correlate well with another chromatographic method and with the specific radioimmunoassay.
Collapse
|
95
|
Varagnolo M, Plebani M, Mussap M, Nemetz L, Paleari CD, Burlina A. Caffeine as indicator of metabolic functions of microsomal liver enzymes. Clin Chim Acta 1989; 183:91-4. [PMID: 2548774 DOI: 10.1016/0009-8981(89)90278-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
96
|
Secchiero S, Mussap M, Zaninotto M, Bertorelle R, Burlina A. Serum arylesterase (paraoxonase) activity following myocardial infarction. Clin Chim Acta 1989; 183:71-5. [PMID: 2548773 DOI: 10.1016/0009-8981(89)90274-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
97
|
Blijenberg BG, Braconnier F, Vallez JM, Burlina A, Plebani M, Celadin M, Haeckel R, Römer M, Hänseler E, De Schrijver G. European multicentre evaluation of the ABBOTT Spectrum clinical chemistry analyzer. JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY. ZEITSCHRIFT FUR KLINISCHE CHEMIE UND KLINISCHE BIOCHEMIE 1989; 27:369-91. [PMID: 2666564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The analytical performance of the selective multitest ABBOTT Spectrum analyser was studied according to the ECCLS guidelines and partly the CERMAB protocol in a multicentre evaluation involving laboratories from six European countries. Fifteen analytes, including the electrolytes sodium, potassium and chloride, were measured each in at least 3 laboratories, all at 37 degrees C, except the electrolytes, which are measured at room temperature. The trial lasted approximately three months and involved the collection of over 60,000 data points. It yielded the following results: 1. The precision was at least as good as the precision obtained with the comparison instruments. The majority of the coefficients of variation were between 1 and 4%. 2. The recovery for method assigned control sera values was, with few exceptions, within 10%. 3. Good agreement with respect to the method assigned values of control materials and method comparison with patient specimens to different instruments (e.g. SMAC, Hitachi 737, RA 1000) was found. 4. No drift was observed. 5. Reagent-related carry-over was not found. Specimen-related carry-over was detected in some cases, the deviation being of little or no clinical significance. 6. The manufacturer's claims regarding method linearity were as stated or exceeded. 7. The open system capability was tested and rated as very convenient. 8. The practicability of the instrument was very good.
Collapse
|
98
|
Plebani M, Chiaramonte M, Floreani A, Bertorelle R, Naccarato R, Burlina A. Two new serum immunoassays (RIA and EIA) for the determination of M2 antimitochondrial antibodies in primary biliary cirrhosis. Clin Chim Acta 1989; 181:201-6. [PMID: 2661058 DOI: 10.1016/0009-8981(89)90189-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
99
|
Fabris C, Basso D, Del Favero G, Piccoli A, Angonese C, Di Mario F, Plebani M, Bonvicini P, Burlina A, Naccarato R. Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis. Nephron Clin Pract 1989; 51:56-60. [PMID: 2563574 DOI: 10.1159/000185243] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Urinary excretion of alpha-glucosidase (AGL), gamma-glutamyltransferase (GGT) and ribonuclease (RNase), and serum amylase and immunoreactive trypsin (IRT) were determined in 38 control subjects, 48 patients with pancreatic cancer, 77 with chronic pancreatitis and 47 with extrapancreatic diseases in order to ascertain the presence of a renal tubular damage and to investigate its etiology. A significantly increased frequency of pathological results for all urinary enzymes was documented in the various groups of patients as compared to controls. Significant correlations were detected among AGL, GGT and RNase. Considering the subjects as a whole, GGT and RNase excretions correlated with serum IRT and amylase; the two urinary enzymes were found to be higher when jaundice was present. In chronic pancreatic disease enzymuria was related to increased serum pancreatic enzymes; in extrapancreatic diseases it was associated to hyperbilirubinemia. The vast majority of patients with pancreatic cancer and elevated urinary enzymes presented hepatic metastases and/or jaundice. We can conclude that an anatomical and functional tubular impairment is detectable in some patients with chronic pancreatic and extrapancreatic diseases. Tubular damage seems to least in part to be related to pancreatic inflammation and necrosis in chronic pancreatic disease, while jaundice may be found to play an important role in diseases of the hepatobiliary tract. In pancreatic cancer, liver dysfunction (presence of liver metastases and/or extrahepatic cholestasis) also appears to be involved in altering tubular cells.
Collapse
|
100
|
Zaninotto M, Bertorelle R, Secchiero S, Plebani M, Burlina A. Assay of pancreatic amylase with use of monoclonal antibodies evaluated. Clin Chem 1988; 34:2552-5. [PMID: 2461818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
To evaluate a new method for measuring pancreatic amylase in serum, in which the salivary isoenzyme is inhibited with a specific monoclonal antibody, we determined the activity of pancreatic and salivary amylase in sera from 103 healthy subjects and from 114 hospitalized patients having a wide range of total amylase activities. CVs for the proposed method ranged from 0.8% to 5.1% (within day) and from 2.3% to 6.6% (day to day). Results correlated well with those obtained by the wheat-germ inhibition method (r = 0.998) and by electrophoresis on cellulose acetate. Analytical-recovery studies confirmed the good specificity of the monoclonal antibody for salivary amylase (97%) and its low cross-reactivity (0.6%) toward pancreatic amylase. The assay procedure presents a wide range of linearity (141-1817 U/L) and can easily be adapted to an automated kinetic system. We found the proposed method suitable for routine determinations of pancreatic amylase.
Collapse
|